| |
 |
 |
 |
 |
 |
 |
 |
| HOME
> About Us > Strategy |
|
|
|
Genetic medication is where medicine is heading in the next generation. To date no actual product has been developed as yet. Given the circumstances, our company selects development areas considering the following:
|
 |
First, we study lifestyle-related diseases and chronic conditions, for which no satisfactory effects can be obtained with conventional drugs. Lifestyle-related diseases, such as arteriosclerosis and diabetes mellitus, have spread around the world as the result of changes in eating habits, as well as due to other factors. Coping with lifestyle-related diseases is one of the most significant challenges the human race is facing. Developing effective drugs against these diseases is one of the requirements that the pharmaceutical industry must fulfill for the benefit of society, while from a business perspective, a considerable market opportunity awaits such product developers.
Second, genetic medication provides us with technological advantages: instead of working on conventional low-molecular compounds, we specialize in genetic and nucleic acid medicine.
Essentially our business has two axes: horizontal (genetic medicine) and vertical (lifestyle-related diseases/chronic conditions). The representative agent is the HGF (Hepatocyte Growth Factor) genetic medicine. Applying the HGF's vascularization effects shall provide for better treatment of arteriosclerosis obliterans, which clogs the arteries in the legs, as well as ischemic heart disease (IHD), deteriorating blood circulation in the heart. Unlike cancers, often untraceable due to different gene re-combinations involved, the two disorders listed above can be treated with a method of physics - vascularization. Therefore, among all the genetic medication types, treatment of these diseases represents the field that is nearest to practical applications. NFκB decoy oligos, agents that cure atopic dermatitis, rheumatoid arthritis, and other inflammatory diseases with synthetic nucleic acid to control genetic functions, also belong to the genetic medicine / chronic conditions category.
Beginning with a few areas, we will further expand the applications. More specifically, using HGF applications for nerve extensions, we plan to develop drugs for Parkinson disease. In addition, we actively seek new technological advancements that will lead to the development of revolutionary drugs.
The development of genetic medicine is functionally related to the process of vector formation - a mechanism enabling the appropriate delivery of active agents to the target cells. Without this technology, a new pharmaceutical drug is ineffective, regardless of how good an agent's efficacy may be. This is why drugs and vector mechanism development are mutually dependent, just like a car cannot run without wheels.
Based on this perspective, our company is pushing forward with the development of the HVJ (Hemagglutinating Virus of Japan) envelope vector - an "envelope" containing different kinds of agents, such as protein and low molecular compounds, that delivers them to the affected body parts. The HVJ envelope vector potentially has a broad range of applications, including DDS (Drug Delivery System) and analyses of genetic functionality.
With these considerations, our business activities revolve around research and development. Our present projects rely on the assumption that we closely cooperate with pharmaceutical companies. We receive development assistance, in addition to initial contract and principal payments. This is how we see minimizing the financial risks, expecting an income stream from royalties and licensing fees once a product is marketed. In the future, we plan to develop proprietary drugs by ourselves in the future (provided the business environment permits to do so).
|
|
